With potential multibillion-dollar buyout or drug approval, Cytokinetics’ 1st employee close to taking company to finish line

Novartis AG is in advanced talks to buy Cytokinetics, the Wall Street Journal reported Monday, just weeks after Cytokinetics disclosed strong late-stage clinical trial results for a heart failure drug.
Click here to view original post